Sialyloligosaccharides inhibit cholera toxin binding to the GM1 receptor

Sinclair, Haydn R.; Smejkal, Christopher W.; Glister, Claire; Kemp, Fred; Heuvel, Ellen G. H. M. van den; Slegte, Jaap de; Gibson, Glenn R.; Rastall, Robert A.

doi:10.1016/j.carres.2008.07.008

Cited by 26 publications

(21 citation statements)

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fucosylated oligosaccharides such as Fuc-α-2-Gal-β-4-GlcNAc are effective inhibitors of adhesion between Campylobacter jejuni and human cells. Infants that are breastfed with milk containing elevated levels of these oligosaccharides suffered diarrhea less frequently than those fed with milk containing low levels of these oligosaccharides (Morrow et al, 2005; Newburg et al, 2005; Sinclair et al, 2008). Sinclair et al, (2008) demonstrated the inhibition of cholera toxin binding to the GM1 receptor by sialyloligosaccharides (SOS).…”

Section: Anti-adhesion Therapymentioning

confidence: 99%

“…Anti-adhesion therapy offers many advantages over conventional chemotherapies including efficacy, reduction of multiple side effects and environmental sensibility (Sharon, 2006). Many anti-adhesion carbohydrates are found as normal constituents of our diets or endogenously (Kontiokari et al, 2001; Morrow et al, 2005; Newburg et al, 2005; Sharon, 2006; Sinclair et al, 2008). Drugs using these compounds may not be safe and their safety is yet to be determined.…”

Section: Anti-adhesion Therapymentioning

confidence: 99%

See 1 more Smart Citation

A glycobiology review: Carbohydrates, lectins and implications in cancer therapeutics

2011

View full text Add to dashboard Cite

This review is intended for general readers who would like a basic foundation in carbohydrate structure and function, lectin biology and the implications of glycobiology in human health and disease, particularly in cancer therapeutics. These topics are among the hundreds included in the field of glycobiology and are treated here because they form the cornerstone of glycobiology or the focus of many advances in this rapidly expanding field.

show abstract

Section: Anti-adhesion Therapymentioning

confidence: 99%

Section: Anti-adhesion Therapymentioning

confidence: 99%

A glycobiology review: Carbohydrates, lectins and implications in cancer therapeutics

2011

View full text Add to dashboard Cite

show abstract

“…Sinclair et al (2008) demonstrated that this interference was not unique to bacterial cells, with a study using sialyloligosaccharide shown to inhibit binding of the cholera toxin to its receptor on the cell. FOS and GOS have been linked to increased mucin production (Ten Bruggencate et al, 2006;Leforestier et al, 2009) resulting in reduced bacterial translocation and consequently, a lower incidence of pathogenic infection (Looijer-van Langen and Dieleman, 2009).…”

Section: Prebiotics and Mucinsmentioning

confidence: 99%

“…Other compounds studied for their prebiotic potential include mannan-oligosaccharides (MOS) (Yang et al, 2008b), β-1,4-mannobiose (MNB) (Ibuki et al, 2010), sialyl-oligosaccharides (SOS) (Sinclair et al, 2008), xylo-oligosaccharides (XOS) (Xu et al, 2009), germinated barley foodstuff (GBF) (Kanauchi et al, 2008), epilactose Watanabe et al, 2008), arabinoxylanoligosaccharides (AXOS) (Maki et al, 2012) and chito-oligosaccharides (COS) (Liu et al, 2008).…”

Section: Prebioticsmentioning

confidence: 99%

Prebiotics: A Potential Treatment Strategy for the Chemotherapy-damaged Gut?

Wang

Geier

Howarth

2014

Critical Reviews in Food Science and Nutrition

View full text Add to dashboard Cite

Mucositis, characterized by ulcerative lesions along the alimentary tract, is a common consequence of many chemotherapy regimens. Chemotherapy negatively disrupts the intestinal microbiota, resulting in increased numbers of potentially pathogenic bacteria, such as Clostridia and Enterobacteriaceae, and decreased numbers of "beneficial" bacteria, such as Lactobacilli and Bifidobacteria. Agents capable of restoring homeostasis in the bowel microbiota could therefore be applicable to mucositis. Prebiotics are indigestible compounds, commonly oligosaccharides, which seek to reverse chemotherapy-induced intestinal dysbiosis through selective colonization of the intestinal microbiota by probiotic bacteria. In addition, evidence is emerging that certain prebiotics contribute to nutrient digestibility and absorption, modulate intestinal barrier function through effects on mucin expression, and also modify mucosal immune responses, possibly via inflammasome-mediated processes. This review examines the known mechanisms of prebiotic action and explores their potential to reduce the severity of chemotherapy-induced mucositis in the intestine. MUCOSITISThe treatment of cancer by chemotherapy, sometimes in combination with radiotherapy, is associated with an array of acute side-effects, including alopecia, neutropenia and nausea (Logan et al., 2007). Furthermore, these treatments can also induce inflammation and deterioration of the mucosal membranes of the alimentary tract, a condition referred to as mucositis. Mucositis can occur throughout the entire gastrointestinal tract (Gibson et al., 2005); however, it most commonly affects the mucosa of the mouth (oral mucositis) and small intestine (gastrointestinal mucositis), with symptoms including pain, vomiting, bloating, and diarrhoea. Severe cases are often associated with secondary complications such as malnutrition and septicaemia, resulting in poor patient outcomes. Indeed, the pathobiology of mucositis is influenced by the nature of the causative agent (Logan et al., 2009), with temporal variations in pathogenesis, in addition to the location and severity of damage (Logan et al., 2009). Consequently, the multi-factorial nature of mucositis makes it a difficult condition to understand, and subsequently treat.Despite mucositis being one of the most common side-effects of cancer treatment (Choi et al., 2007) its incidence and severity is highly variable, and is dependent on the treatment regimen and individual variation in terms of tolerability . Approximately 40% of all patients undergoing chemotherapy develop mucositis (Gibson et al., 2002; with this number rising to between 60% and 100% in patients receiving high-dose chemotherapy regimens for conditions such as the haematological malignancies (Gibson et al., 2002;. To date, effective treatments for intestinal mucositis have been elusive. Potential treatment options are limited by the requirement for treatments to protect the mucosa and promote the repair process, without compromising cytotoxic effects on the ...

show abstract

“…80,81 Prebiotic compounds include inulin, 82 a plant derived fructan; lactulose 83 ; galacto-oligosaccharide 84 ; and fructo-oligosaccharide. 85 Other compounds studied for their prebiotic potential include arabinoxylan-oligosaccharides, 86 chito-oligosaccharides, 87 epilactose, 88 germinated barley foodstuff, 89 mannan-oligosaccharides, 90 sialyl-oligosaccharides, 91 xylo-oligosaccharides, 92 and b-1,4-mannobiose.…”

Section: Prebioticsmentioning

confidence: 99%

Newly Developed Synbiotics and the Chemotherapy-Damaged Gut

Wang

Bastian

Howarth

2013

J Evid Based Complementary Altern Med

View full text Add to dashboard Cite

Mucositis is a common side-effect of cancer chemotherapy and radiotherapy. Features of mucositis include erythema, ulceration, and inflammation of the gastrointestinal tract accompanied by clinical symptoms of abdominal pain and digestive disturbances. New treatment strategies are required. Experimental evidence is accumulating showing therapeutic promise for new nutraceutical agents including probiotic bacteria, probiotic-derived factors, prebiotics, and plant extracts. However, the targeted development of new combinations of these agents (synbiotics) to combat mucositis remains largely unexplored. The current review addresses the potential for these nutraceutical agents to reduce the severity of chemotherapy-damaged mucositis by strategically aligning their underlying mechanism of action with features of mucositis pathogenesis. The potential for certain plant extracts to act as prebiotics, in combination with probiotics or their derived factors, is further investigated. These unique synbiotic formulations could form the basis of a new naturally sourced adjunctive approach to cancer chemotherapy.

show abstract

Sialyloligosaccharides inhibit cholera toxin binding to the GM1 receptor

Cited by 26 publications

References 72 publications

A glycobiology review: Carbohydrates, lectins and implications in cancer therapeutics

A glycobiology review: Carbohydrates, lectins and implications in cancer therapeutics

Prebiotics: A Potential Treatment Strategy for the Chemotherapy-damaged Gut?

Newly Developed Synbiotics and the Chemotherapy-Damaged Gut

Contact Info

Product

Resources

About